<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-4F4JP2JB/a9b2adf9-72e6-4ba7-b458-ac49cb77bb33/HTML"><dcterms:extent>20 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-4F4JP2JB/50fd9dcb-8775-42ec-aed6-2ab017df21b8/PDF"><dcterms:extent>190 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-4F4JP2JB/bf5049c8-2f3b-45bf-a44d-7d338b5e6324/TEXT"><dcterms:extent>17 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-4F4JP2JB"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>2001</dcterms:issued><dc:creator>Bračko, Matej</dc:creator><dc:creator>Golouh, Rastko</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:35</dc:format><dc:format xml:lang="sl">6 strani</dc:format><dc:format xml:lang="sl">str. 47-52</dc:format><dc:identifier>COBISSID:12888281</dc:identifier><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-4F4JP2JB</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Association of Radiology and Oncology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="en">Classification</dc:subject><dc:subject xml:lang="en">diagnostika</dc:subject><dc:subject xml:lang="sl">histologija</dc:subject><dc:subject xml:lang="en">Neoplasm staging</dc:subject><dc:subject xml:lang="en">Pathology</dc:subject><dc:subject xml:lang="en">Prognosis</dc:subject><dc:subject xml:lang="en">Questionnaires</dc:subject><dc:subject xml:lang="sl">rak (medicina)</dc:subject><dc:subject xml:lang="en">Sarcoma</dc:subject><dc:subject xml:lang="sl">sarkom</dc:subject><dc:subject xml:lang="en">Soft tissue neoplasms</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">What is current practice in soft tissue sarcoma grading?|</dc:title><dc:description xml:lang="sl">Purpose. Most published grading systems of soft tissue sarcomas (STS) are somewhat subjective and it seems that there is no definite consensus among experts which of them is the most effective. The aim of this study was to collect data from practicing pathologists and to get some insight in the practice of STS grading. Subjects. A questionnaire was sent to 135 pathologists chosen randomly. Results. There were 88 responders from 30 countries from 5 continents. Most responders (85%) grade STS, more frequently in Europe than in non-European countries. Three-grade system is preferred by both European and non-European pathologists, who use it in almost 77% and 67%,respectively. They apply the criteria set by FNCLCC in 37.3%, by NCI in 24%, by Broders in 12% and by Markhede in 1.4%. In Europe, FNCLCC system is the most widely used. Beside classical histological criteria, other modern methods are applied by more than one half of the responders. Immunohistochemical evaluation of proliferation markers is the method most widely used, followed by molecular markers and DNA flow cytometry. Conclusion.The results of our study indicate that most pathologists consider histologic grade of STS as a valuable, however not completely satisfactory predictor of a patients survival</dc:description><dc:description xml:lang="sl">Namen. Večina objavljenih sistemov gradiranja sarkomov mehkih tkiv (SMT) je vsaj delno subjektivnih. Zdi se, da med strokovnjaki ni popolnega soglasja o tem, kateri od njih je najboljši. Z raziskavo smo skušali zbrati podatke med patologi iz prakse in tako vsaj delno ugotoviti, kakšna je praksa gradiranja SMT. Anketiranci. Naključno izbranim 135 patologom smo poslali posebej prirejen vprašalnik. Rezultati. Dobili smo 88 odgovorov patologov iz 30 dežel iz vseh petih kontinentov. Večina patologov (85%) gradira SMT, pogosteje v Evropi kot v neevropskih deželah. Oboji uporabljajo najpogosteje sistem treh stopenj, prvi v 77%, drugi 67%. V praksi so najpogostejši kriteriji FNCLCC (37.3%), NCI (24%), Brodersa (12%) in Markhedeja (1.4%). V Evropi je najbolj popularen sistem FNCLCC. Več kot pol anketirancev uporablja poleg klasičnih histoloških kriterijev tudi moderne metode. Najpogostejša je imunohistokemija,sledijo molekularni markerji in DNA pretočna citometrija. Razprava. Rezultati raziskave kažejo, da imajo patologi histološko gradiranje SMT za koristen, čeprav ne povsem zadovoljiv kazalec bolnikovega preživetja</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-4F4JP2JB"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-4F4JP2JB" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-4F4JP2JB/50fd9dcb-8775-42ec-aed6-2ab017df21b8/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo radiologije in onkologije</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-4F4JP2JB/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-4F4JP2JB" /></ore:Aggregation></rdf:RDF>